Arkolith/Insider Trading/CADL/Form 4/A

Tyagarajan Seshu

Chief Technology OfficerCandel Therapeutics, Inc. (CADL) · full profile →Form 4/A · filed Mar 20, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$276K
Net Open-Market Flow
-$276K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2025Sell(S)31K$8.82$276K86K
Mar 17, 2025Option exercise(M)20K$1.29$26K117K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 17, 2025Option exercise(M)20K—$070K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0000950170-25-042724) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML